NCM
IBRX icon

Nantahala Capital Management’s ImmunityBio IBRX Stock Holding History

Nantahala Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-52,771
Closed -$703K – 125
2020
Q4 		$703K Buy
52,771
+2,158
+4% +$20.8K 0.02% 108
2020
Q3 		$351K Buy
50,613
+613
+1% +$6.11K 0.01% 110
2020
Q2 		$614K Buy
+50,000
New +$282K 0.02% 108

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nantahala Capital Management's IBRX Position: Q1 2021 in Review

Nantahala Capital Management sold out of ImmunityBio (IBRX) in Q1 2021, closing a stake of 52,771 shares — an estimated $703K sold.

Nantahala Capital Management first reported a position in IBRX in Q2 2020 and held it in 3 quarters. The position peaked at $703K in Q4 2020. 126 funds tracked by Wall St. Rank hold IBRX as of Q1 2021.

  • Nantahala Capital Management reported no remaining ImmunityBio position as of Q1 2021 after selling out during the quarter.
  • Nantahala Capital Management sold 52,771 ImmunityBio shares in Q1 2021, an estimated $703K.
  • Nantahala Capital Management first reported a position in ImmunityBio in Q2 2020 and held it in 3 quarters.
  • Nantahala Capital Management's ImmunityBio position peaked at $703K in Q4 2020.
  • 126 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2021.

Based on Nantahala Capital Management's 13F filing for Q1 2021, filed 14 May 2021.